Literature DB >> 23788362

Assessing heterogeneity of treatment effect in a clinical trial with the proportional interactions model.

Stephanie A Kovalchik1, Ravi Varadhan, Carlos O Weiss.   

Abstract

Understanding how individuals vary in their response to treatment is an important task of clinical research. For standard regression models, a proportional interactions model first described by Follmann and Proschan (1999) offers a powerful approach for identifying effect modification in a randomized clinical trial when multiple variables influence treatment response. In this paper, we present a framework for using the proportional interactions model in the context of a parallel-arm clinical trial with multiple prespecified candidate effect modifiers. To protect against model misspecification, we propose a selection strategy that considers all possible proportional interactions models. We develop a modified Bonferroni correction for multiple testing that accounts for the positive correlation among candidate models. We describe methods for constructing a confidence interval for the proportionality parameter. In simulation studies, we show that our modified Bonferroni adjustment controls familywise error and has greater power to detect proportional interactions compared with multiplcity-corrected subgroup analyses. We demonstrate our methodology by using the Studies of Left Ventricular Dysfunction Treatment trial, a placebo-controlled randomized clinical trial of the efficacy of enalapril to reduce the risk of death or hospitalization in chronic heart failure patients. An R package called anoint is available for implementing the proportional interactions methodology.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  effect modification; heterogeneity of treatment effect; interaction; risk stratification; subgroup analysis

Mesh:

Substances:

Year:  2013        PMID: 23788362     DOI: 10.1002/sim.5881

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  13 in total

1.  Evaluation of biomarkers for treatment selection using individual participant data from multiple clinical trials.

Authors:  Chaeryon Kang; Holly Janes; Parvin Tajik; Henk Groen; Ben Mol; Corine Koopmans; Kim Broekhuijsen; Eva Zwertbroek; Maria van Pampus; Maureen Franssen
Journal:  Stat Med       Date:  2018-02-14       Impact factor: 2.373

2.  Using internally developed risk models to assess heterogeneity in treatment effects in clinical trials.

Authors:  James F Burke; Rodney A Hayward; Jason P Nelson; David M Kent
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-01-14

3.  The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration.

Authors:  David M Kent; David van Klaveren; Jessica K Paulus; Ralph D'Agostino; Steve Goodman; Rodney Hayward; John P A Ioannidis; Bray Patrick-Lake; Sally Morton; Michael Pencina; Gowri Raman; Joseph S Ross; Harry P Selker; Ravi Varadhan; Andrew Vickers; John B Wong; Ewout W Steyerberg
Journal:  Ann Intern Med       Date:  2019-11-12       Impact factor: 25.391

4.  Preventing asthma in high risk kids (PARK) with omalizumab: Design, rationale, methods, lessons learned and adaptation.

Authors:  Wanda Phipatanakul; David T Mauger; Theresa W Guilbert; Leonard B Bacharier; Sandy Durrani; Daniel J Jackson; Fernando D Martinez; Anne M Fitzpatrick; Amparito Cunningham; Susan Kunselman; Lisa M Wheatley; Cindy Bauer; Carla M Davis; Bob Geng; Kirsten M Kloepfer; Craig Lapin; Andrew H Liu; Jacqueline A Pongracic; Stephen J Teach; James Chmiel; Jonathan M Gaffin; Matthew Greenhawt; Meera R Gupta; Peggy S Lai; Robert F Lemanske; Wayne J Morgan; William J Sheehan; Jeffrey Stokes; Peter S Thorne; Hans C Oettgen; Elliot Israel
Journal:  Contemp Clin Trials       Date:  2020-11-24       Impact factor: 2.261

Review 5.  Subgroup analyses in confirmatory clinical trials: time to be specific about their purposes.

Authors:  Julien Tanniou; Ingeborg van der Tweel; Steven Teerenstra; Kit C B Roes
Journal:  BMC Med Res Methodol       Date:  2016-02-18       Impact factor: 4.615

Review 6.  Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review.

Authors:  Thomas Ondra; Alex Dmitrienko; Tim Friede; Alexandra Graf; Frank Miller; Nigel Stallard; Martin Posch
Journal:  J Biopharm Stat       Date:  2016       Impact factor: 1.051

7.  Bayesian analysis of heterogeneous treatment effects for patient-centered outcomes research.

Authors:  Nicholas C Henderson; Thomas A Louis; Chenguang Wang; Ravi Varadhan
Journal:  Health Serv Outcomes Res Methodol       Date:  2016-09-20

8.  Development and evaluating multimarker models for guiding treatment decisions.

Authors:  Parvin Tajik; Mohammad Hadi Zafarmand; Aeilko H Zwinderman; Ben W Mol; Patrick M Bossuyt
Journal:  BMC Med Inform Decis Mak       Date:  2018-06-28       Impact factor: 2.796

9.  The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement.

Authors:  David M Kent; Jessica K Paulus; David van Klaveren; Ralph D'Agostino; Steve Goodman; Rodney Hayward; John P A Ioannidis; Bray Patrick-Lake; Sally Morton; Michael Pencina; Gowri Raman; Joseph S Ross; Harry P Selker; Ravi Varadhan; Andrew Vickers; John B Wong; Ewout W Steyerberg
Journal:  Ann Intern Med       Date:  2019-11-12       Impact factor: 25.391

10.  Subgroup identification in clinical trials via the predicted individual treatment effect.

Authors:  Nicolás M Ballarini; Gerd K Rosenkranz; Thomas Jaki; Franz König; Martin Posch
Journal:  PLoS One       Date:  2018-10-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.